In vitro and in vivo characterisation of ASP9521: A novel, selective, orally bioavailable inhibitor of 17β-hydroxysteroid dehydrogenase type 5 (17βHSD5; AKR1C3)

Investigational New Drugs

Volumn 32, Issue 5, 2014, Pages 860-870

  Kikuchi, Aya ^a   Furutani, Takashi ^a   Azami, Hidenori ^a   Watanabe, Kazushi ^a   Niimi, Tatsuya ^a   Kamiyama, Yoshiteru ^a   Kuromitsu, Sadao ^a   Baskin Bey, Edwina ^b   Heeringa, Marten ^b   Ouatas, Taoufik ^b   Enjo, Kentaro ^a  

^a ASTELLAS PHARMA INC   (Japan)

^b Astellas Pharma Global Development   (Netherlands)

Author keywords

17beta hydroxysteroid dehydrogenase type 5; Aldo keto reductase 1C3; Androgen deprivation therapy; Androgen synthesis; Castration resistant prostate cancer; Testosterone

Indexed keywords

1-(1-((5-METHOXY-1H-INDOL-2-YL)CARBONYL)PIPERIDIN-4-YL)-2-METHYLPROPAN-2-OL; AKR1C6 PROTEIN, MOUSE; ANDROSTENEDIONE; ENZYME INHIBITOR; ESTRADIOL 17BETA DEHYDROGENASE; INDOLE DERIVATIVE; PIPERIDINE DERIVATIVE; TESTOSTERONE;

ANIMAL; ANTAGONISTS AND INHIBITORS; BAGG ALBINO MOUSE; BIOAVAILABILITY; BLOOD; DOG; HUMAN; MACACA FASCICULARIS; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; PROSTATE TUMOR; RAT; SPRAGUE DAWLEY RAT; TUMOR CELL LINE;

ADMINISTRATION, ORAL; ANDROSTENEDIONE; ANIMALS; BIOLOGICAL AVAILABILITY; CELL LINE, TUMOR; DOGS; ENZYME INHIBITORS; ESTRADIOL DEHYDROGENASES; HUMANS; INDOLES; MACACA FASCICULARIS; MALE; MICE, INBRED BALB C; PIPERIDINES; PROSTATIC NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; TESTOSTERONE;

EID: 84927596103     PISSN: 01676997     EISSN: 15730646     Source Type: Journal    
DOI: 10.1007/s10637-014-0130-5     Document Type: Article

References (36)

1. Huggins C, Hodges CV (1941) Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. Cancer Res 1:293-297
2. Huggins C, Stevens RE, Hodges CV (1941) Studies on prostatic cancer. II. The effects of castration on advanced carcinoma of the prostate gland. Arch Surg 43:209-223
3. Mottet N, Bastian PJ, Bellmunt J, van den Bergh RCN, Bolla M, van Casteren NJ, Cornford P, Joniau S, Mason MD, Matveev V, van der Kwast TH, van der Poel H, Rouvière O, Wiegel T (2014) EAU guidelines on prostate cancer. Update April 2014. European Association of Urology. http://www.uroweb.org/guidelines/onlineguidelines/.Accessed 25 April 2014
4. Harris WP, Mostaghel EA, Nelson PS, Montgomery B (2009) Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion. Nat Clin Pract Urol 6:76-85. doi:10.1038/ncpuro1296
5. Zong Y, Goldstein AS (2013) Adaptation or selection - mechanisms of castration-resistant prostate cancer. Nat Rev Urol 10:90-98. doi:10.1038/nrurol.2012.237
6. Karantanos T, Corn PG, Thompson TC (2013) Prostate cancer progression after androgen deprivation therapy: mechanisms of castrate resistance and novel therapeutic approaches. Oncogene 32:5501-5511. doi:10.1038/onc.2013.206
7. Labrie F (2011) Blockade of testicular and adrenal androgens in prostate cancer treatment. Nat Rev Urol 8:73-80. doi:10.1038/nrurol.2010.231
8. Adeniji AO, Chen M, Penning TM (2013) AKR1C3 as a target in castrate resistant prostate cancer. J Steroid Biochem Mol Biol 137:136-149. doi:10.1016/j.jsbmb.2013.05.012
9. Fung KM, Samara ENS, Wong C, Metwalli A, Krlin R, Bane B, Liu CZ, Yang JT, Pitha JV, Culkin DJ, Kropp BP, Penning TM, Lin HK (2006) Increased expression of type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase (AKR1C3) and its relationship with androgen receptor in prostate carcinoma. Endocr Relat Cancer 13:169-180. doi:10.1677/erc.1.01048
10. Dufort I, Rheault P, Huang XF, Soucy P, Luu-The V (1999) Characteristics of a highly labile human type 5 17β-hydroxysteroid dehydrogenase. Endocrinology 140:568-574. doi:10.1210/endo.140.2.6531
11. Lin HK, Steckelbroeck S, Fung KM, Jones AN, Penning TM (2004) Characterization of a monoclonal antibody for human aldo-keto reductase AKR1C3 (type 2 3α-hydroxysteroid dehydrogenase/type 5 17β-hydroxysteroid dehydrogenase); immunohistochemical detection in breast and prostate. Steroids 69:795-801. doi:10.1016/j.steroids.2004.09.014
12. Azzarello J, Fung KM, Lin HK (2008) Tissue distribution of human AKR1C3 and rat homolog in the adult genitourinary system. J Histochem Cytochem 56:853-861. doi:10.1369/jhc.2008.951384
13. Wako K, Kawasaki T, Yamana K, Suzuki K, Jiang S, Umezu H, Nishiyama T, Takahashi K, Hamakubo T, Kodama T, NaitoM(2008) Expression of androgen receptor through androgen-converting enzymes is associated with biological aggressiveness in prostate cancer. J Clin Pathol 61:448-454. doi:10.1136/jcp.2007.050906
14. Stanbrough M, Bubley GJ, Ross K, Golub TR, Rubin MA, Penning TM, Febbo PG, Balk SP (2006) Increased expression of genes converting adrenal androgens to testosterone in androgen-independent prostate cancer. Cancer Res 66:2815-2825. doi:10.1158/0008-5472.CAN-05-4000
15. Hamid ARAH, Pfeiffer MJ, Verhaegh GW, Schaafsma E, Brandt A, Sweep FCGJ, Sedelaar JPM, Schalken JA (2012) Aldo-keto reductase family 1 member C3 (AKR1C3) is a biomarker and therapeutic target for castration-resistant prostate cancer. Mol Med 18:1449-1455. doi:10.2119/molmed.2012.00296
16. Pfeiffer MJ, Smit FP, Sedelaar JPM, Schalken JA (2011) Steroidogenic enzymes and stemcellmarkers are upregulated during androgen deprivation in prostate cancer. Mol Med 17:657-664. doi:10.2119/molmed.2010.00143
17. Montgomery RB, Mostaghel EA, Vessella R, Hess DL, Kalhorn TF, Higano CS, True LD, Nelson PS (2008)Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth. Cancer Res 68:4447-4454. doi:10.1158/0008-5472.CAN-08-0249
18. Hofland J, van WeerdenWM, Dits NFJ, Steenbergen J, van Leenders GJLH, Jenster G, Schröder FH, de Jong FH (2010) Evidence of limited contributions for intratumoral steroidogenesis in prostate cancer. Cancer Res 70:1256-1264. doi:10.1158/0008-5472.CAN-09-2092
19. Jernberg E, Thysell E, Bovinder Ylitalo E, Rudolfsson S, Crnalic S, Widmark A, Bergh A, Wikström P (2013) Characterization of prostate cancer bone metastases according to expression levels of steroidogenic enzymes and androgen receptor splice variants. PLoSOne 8:e77407. doi:10.1371/journal.pone.0077407
20. Mitsiades N, Sung CC, Schultz N, Danila DC, He B, Eedunuri VK, FleisherM, Sander C, Sawyers CL, Scher HI (2012) Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors. Cancer Res 72:6142-6152. doi:10.1158/0008-5472.CAN-12-1335
21. Loriot Y, Fizazi K, Jones RJ, Van den Brande J, Molife RL, Omlin A, James ND, Baskin-Bey E, Heeringa M, Baron B, Holtkamp G, Ouatas T, De Bono JS (2014) Safety, tolerability and anti-tumour activity of the androgen biosynthesis inhibitor ASP9521 in patients with metastatic castration-resistant prostate cancer: multi-centre phase I/II study. Invest New Drugs. doi:10.1007/s10637-014-0101-x
22. Kazushi Watanabe, Akio Kakefuda, Minoru Yasuda, Yasushi Amano, Kentaro Enjo, Aya Kikuchi, Takashi Furutani, Yoichi Naritomi, Yukio Otsuka, Minoru Okada, Mitsuaki Ohta. Discovery of ASP9521, a novel, potent, selective 17β-HSD5 inhibitor. Poster presented at 246th American Chemical Society meeting, 8 September 2013, Indianapolis, Indiana, USA (MEDI 108). http://abstracts.acs.org//chem/246nm/program/divisionindex.php?nl=1&act=presentations&val=General+Poster+Session&ses=General+Poster+Session&prog=191040. Accessed 25 April 2014
23. Byrns MC, Mindnich R, Duan L, Penning TM (2012) Overexpression of aldo-keto reductase 1C3 (AKR1C3) in LNCaP cells diverts androgen metabolism towards testosterone resulting in resistance to the 5alpha-reductase inhibitor finasteride. J Steroid Biochem Mol Biol 130:7-15. doi:10.1016/j.jsbmb.2011.12.012
24. Rheault P, Charbonneau A, Luu-The V (1999) Structure and activity of the murine type 5 17beta-hydroxysteroid dehydrogenase gene (1). Biochim Biophys Acta 1447:17-24. doi:10.1016/S0167-4781(99)00106-2
25. Schlegel BP, Ratnam K, Penning TM (1998) Retention of NADPH-linked quinone reductase activity in an aldo-keto reductase following mutation of the catalytic tyrosine. Biochemistry 37:11003-11. doi:10.1021/bi980475r
26. Cai C, Chen S, Ng P, Bubley GJ, Nelson PS, Mostaghel EA, Marck B, Matsumoto AM, Simon NI, Wang H, Chen S, Balk SP (2011) Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors. Cancer Res 71:6503-6513. doi:10.1158/0008-5472.CAN-11-0532
27. Mostaghel EA, Marck BT, Plymate SR, Vessella RL, Balk S, Matsumoto AM, Nelson PS, Montgomery RB (2011) Resistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants. Clin Cancer Res 17:5913-5925. doi:10.1158/1078-0432.CCR-11-0728
28. Yepuru M, Wu Z, Kulkarni A, Yin F, Barrett CM, Kim J, Steiner MS, Miller DD, Dalton JT, Narayanan R (2013) Steroidogenic enzyme AKR1C3 is a novel androgen receptor-selective coactivator that promotes prostate cancer growth. Clin Cancer Res 19:5613-5625. doi:10.1158/1078-0432.CCR-13-1151
29. Velic¸a P, Davies NJ, Rocha PP, Schrewe H, Ride JP, Bunce CM (2009) Lack of functional and expression homology between human and mouse aldo-keto reductase 1C enzymes: implications for modelling human cancers. Mol Cancer 8:121. doi:10.1186/1476-4598-8-121
30. Steckelbroeck S, Jin Y, Gopishetty S, Oyesanmi B, Penning TM (2004) Human cytosolic 3α-hydroxysteroid dehydrogenases of the aldo-keto reductase superfamily display significant 3β-hydroxysteroid dehydrogenase activity: implications for steroid hormone metabolism and action. J Biol Chem 279:10784-10795. doi:10.1074/jbc.M313308200
31. Ji Q, Chang L, Stanczyk FZ, OokhtensM, Sherrod A, Stolz A (2007) Impaired dihydrotestosterone catabolism in human prostate cancer: critical role of AKR1C2 as a pre-receptor regulator of androgen receptor signaling. Cancer Res 67:1361-1369. doi:10.1158/0008-5472.CAN-06-1593
32. Attard G, Reid AHM, Yap TA, Raynaud F, Dowsett M, Settatree S, BarrettM, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS (2008) Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven. J Clin Oncol 26:4563-4571. doi:10.1200/JCO.2007.15.9749
33. Adeniji AO, Twenter BM, Byrns MC, Jin Y, Winkler JD, Penning TM (2011) Discovery of substituted 3-(phenylamino)benzoic acids as potent and selective inhibitors of type 5 17β-hydroxysteroid dehydrogenase (AKR1C3). Bioorg Med Chem Lett 21:1464-1468. doi:10.1016/j.bmcl.2011.01.010
34. Watanabe K, Kakefuda A, YasudaM, Enjo K, Kikuchi A, Furutani T, Naritomi Y, Otsuka Y, Okada M, Ohta M (2013) Discovery of 2-methyl-1-{1-[(5-methyl-1H-indol-2-yl)carbonyl]piperidin-4-yl} propan-2-ol: a novel, potent and selective type 5 17β-hydroxysteroid dehydrogenase inhibitor. Bioorg Med Chem 21:5261-5270. doi:10.1016/j.bmc.2013.06.025
35. Chang KH, Li R, Papari-Zareei M, Watumull L, Zhao YD, Auchus RJ, Sharifi N (2011) Dihydrotestosterone synthesis bypasses testosterone to drive castration-resistant prostate cancer. Proc Natl Acad Sci U S A 108:13728-13733. doi:10.1073/pnas.1107898108
36. Mohler JL, Titus MA, Bai S, Kennerley BJ, Lih FB, Tomer KB, Wilson EM (2011) Activation of the androgen receptor by intratumoral bioconversion of androstanediol to dihydrotestosterone in prostate cancer. Cancer Res 71:1486-1496. doi:10.1158/0008-5472.CAN-10-1343